uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Antiphospholipid Antibodies in Patients With Myocardial Infarction.
Show others and affiliations
2018 (English)In: Annals of Internal Medicine, ISSN 0003-4819, E-ISSN 1539-3704, Vol. 170, no 4, p. 277-280Article in journal (Refereed) Epub ahead of print
Abstract [en]

Background: Antiphospholipid syndrome (APS) is defined by arterial, venous, or microvascular thrombosis or obstetric morbidity together with confirmed positive test results, at least 12 weeks apart, for antiphospholipid antibodies (aPLs), including at least 1 of the following tests: anticardiolipin (anti-CL), anti–β2-glycoprotein I (anti-β2GPI), or the functional lupus anticoagulant test (1, 2). Long-term anticoagulation prevents new thrombotic events in most patients with APS. Information on prothrombotic aPLs in patients with myocardial infarction (MI) is conflicting, due to limited sample sizes, selected populations, and nonstandardized methods in previous studies (3). Objective: To assess the frequency of anti-β2GPI and anti-CL of IgG/IgA/IgM isotypes and antinuclear antibodies among patients with first-time MI and matched control participants in a large, multicenter, case–control study. Methods and Findings: The PAROKRANK (Periodontitis and Its Relation to Coronary Artery Disease) study included 805 consecutive patients younger than 75 years who were hospitalized for a first MI at 17 Swedish hospitals between 2010 and 2014 (4). Population control participants (n = 805) were individually matched for age, sex, and region to the patients. Persons who had prior MI or heart valve replacement or were unable to follow the protocol were excluded. Patients were recruited during hospitalization and scheduled for an inclusion visit 6 to 10 weeks later at their local cardiology clinic. The national quality registry SWEDEHEART (www.swedeheart.se) was used to collect medical information at the hospitalization and standardized follow-up data at the inclusion visit. More detailed clinical protocol and extensive questionnaires were also completed at the inclusion visit (5). The same information was collected for the matched control participants. All participants fasted and abstained from smoking for 12 hours before blood sampling at the inclusion visit. Autoantibodies targeting CL and β2GPI of IgG/IgM/IgA isotypes and specific nuclear antigens, as specified in the Table, were analyzed using multiplexed beads (BioPlex 2200 Multiplex Testing, Bio-Rad).

Place, publisher, year, edition, pages
2018. Vol. 170, no 4, p. 277-280
National Category
Cardiac and Cardiovascular Systems
Identifiers
URN: urn:nbn:se:uu:diva-374219DOI: 10.7326/M18-2130ISI: 000458888200023PubMedID: 30357274OAI: oai:DiVA.org:uu-374219DiVA, id: diva2:1280400
Funder
Swedish Heart Lung FoundationSwedish Research CouncilSwedish Society of MedicineSwedish Rheumatism AssociationAvailable from: 2019-01-18 Created: 2019-01-18 Last updated: 2019-08-01Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Lindahl, Bertil
By organisation
Department of Medical SciencesUCR-Uppsala Clinical Research Center
In the same journal
Annals of Internal Medicine
Cardiac and Cardiovascular Systems

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 15 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf